TLPH TLPH
Company Profile ↓Company Overview
TLPH (TLPH) is a publicly traded company listed on with a market capitalization of $66.59M. The valuation, growth and price-trend signals below summarize what matters most to investors and traders evaluating the stock.
Why Investors Should Care
Carries low leverage with a debt-to-equity ratio of 0.31.
Recent Developments
- 5-Year Trend Long-term compounding — revenue CAGR -24.4%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | -24.45% |
| 1 Year: | - |
Stock Price Performance
| 1 Year: | +237.50% |
| 6 Months: | +55.17% |
| 3 Months: | +50.00% |
| 1 Month: | +13.45% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMAAbove
- Price vs 200-DMAAbove
- Golden Cross10d ago
- RSI (14)58.08 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- In a confirmed uptrend (50-DMA above 200-DMA).
CONS
- Revenue declined at -24.4% CAGR over 5 years.
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Jun 2015 | Sep 2015 | Dec 2015 | Mar 2016 | Jun 2016 | Sep 2016 | Dec 2016 | Mar 2017 | Jun 2017 | Sep 2017 | Dec 2017 | Mar 2018 | Jun 2018 | Sep 2018 | Dec 2018 | Mar 2019 | Jun 2019 | Sep 2019 | Dec 2019 | Mar 2020 | Jun 2020 | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 1.92M | 15.43M | 1.73M | 3.02M | 4.53M | 3.37M | 6.43M | 3.11M | 2.66M | 1.49M | 740.00K | 343.00K | 818.00K | 377.00K | 613.00K | 265.00K | 941.00K | 608.00K | 475.00K | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 27.00K | 0 | 1.00K | 0 | 0 |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 2.94M | 3.69M | 3.42M | 3.45M | 3.95M |
| Operating Income | -8.12M | 7.11M | - | -8.52M | -8.32M | -7.97M | - | -12.07M | -9.94M | -8.86M | - | -8.27M | -7.15M | -9.33M | - | -12.32M | -13.36M | -13.53M | - | -15.85M | -6.83M | -9.04M | -9.14M | -10.02M | -8.63M | -4.94M | -13.57M | -6.63M | -5.33M | - | - | - | -4.27M | -3.75M | - | -2.92M | -3.69M | -3.42M | -3.45M | -3.95M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.92M | -3.49M | -4.44M | -3.77M | -3.95M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 0 | 0 | 0 | 0 | 0 | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -2.67M | -3.49M | -4.44M | -3.77M | -2.56M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.90M | 5.07M | -10.55M | -10.98M | -11.09M | -11.40M | -9.68M | -15.55M | -13.06M | -13.01M | -9.88M | -11.59M | -10.54M | -12.46M | -12.56M | -13.67M | -12.41M | -12.73M | -14.42M | -15.93M | -6.61M | -8.93M | -8.96M | -9.85M | -8.38M | -8.67M | 70.66M | -6.75M | -8.15M | -4.37M | -1.36M | -3.95M | -3.83M | -3.35M | - | -2.59M | -3.49M | -4.44M | -3.77M | -2.56M |
| Diluted EPS | -0.20 | 0.11 | -0.24 | -0.25 | -0.24 | -0.25 | -0.21 | -0.34 | -0.29 | -0.28 | -0.20 | - | - | - | - | - | - | - | - | - | - | - | - | -0.08 | -1.40 | - | 8.58 | -0.94 | - | -0.40 | -0.08 | -0.16 | - | - | - | -0.10 | -0.10 | -0.11 | -0.06 | -0.04 |
| R&D Expense | 7.31M | 5.39M | - | 4.17M | 6.28M | 4.62M | - | 6.92M | 4.90M | 3.91M | - | 3.51M | 3.28M | 3.64M | - | 1.38M | 1.16M | 1.06M | - | 1.41M | 813.00K | 956.00K | 969.00K | 724.00K | 1.42M | 836.00K | 1.09M | 799.00K | 1.05M | 1.55M | 1.18M | 1.43M | 1.91M | 2.05M | - | 1.17M | 1.50M | 1.80M | - | 1.65M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | 1.07M | 2.39M | 29.50M | 5.22M | 19.26M | 17.36M | 8.00M | 2.15M | 2.29M | 5.42M | - | 0 | 651.00K | 0 | 28.00K |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 3.75M | 2.59M | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -935.00K | -820.00K | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 20.35M | 17.54M | 15.25M | 13.51M |
| Operating Income | - | - | - | - | - | - | - | -6.67M | -37.65M | -19.95M | -31.96M | -38.68M | -35.73M | -54.20M | -40.96M | - | -20.35M | -16.89M | -15.25M | -13.48M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 61.90M | -9.84M | -12.61M | -14.36M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.12M | 134.00K | 394.00K | 0 |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 59.14M | -10.29M | -13.00M | -14.36M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 5.00K | 13.00K | 0 | - | - |
| Net Income | -3.77M | -9.63M | -20.66M | -20.12M | -14.34M | -20.10M | -33.36M | -23.43M | -33.35M | -24.40M | -43.16M | -51.51M | -47.15M | -53.24M | -40.38M | - | 47.76M | -18.40M | -13.00M | -14.29M |
| Diluted EPS | - | - | - | - | - | - | -1.51 | -0.59 | -0.91 | -0.60 | -0.95 | -1.10 | - | - | - | - | 5.72 | -1.29 | -0.50 | -0.34 |
| R&D Expense | - | - | - | 15.50M | 8.19M | 13.62M | 24.91M | 26.29M | 24.52M | 22.49M | 21.40M | 19.41M | 13.14M | 4.66M | 4.02M | 4.09M | 3.34M | 5.55M | 6.72M | 6.03M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2005 | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | - | - | - | 6.83M | 40.84M | 64.52M | 110.03M | 86.42M | 127.78M | 99.99M | 75.55M | 120.53M | 91.36M | 66.30M | - | 47.49M | 20.39M | 18.24M | 29.72M |
| Current Assets | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 24.57M | 11.58M | 9.42M | 20.90M |
| Cash & Equivalents | - | - | - | 6.07M | 7.15M | 3.06M | 7.79M | 47.93M | 88.40M | 60.04M | 107.92M | 80.31M | 52.90M | 87.97M | 14.68M | 27.27M | - | 15.28M | 5.72M | 8.86M | 5.89M |
| Inventory | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 1.11M | 1.18M | - | - | - |
| Receivables | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 160.00K | 309.00K | - | - | - |
| Total Liabilities | - | - | - | - | - | 16.78M | 23.37M | 30.67M | 36.87M | 39.76M | 94.67M | 105.33M | 112.06M | 116.28M | 132.77M | 122.05M | - | 25.67M | 6.29M | 10.23M | 12.68M |
| Current Liabilities | - | - | - | - | - | 13.41M | 7.84M | 14.33M | 6.87M | 13.73M | 12.78M | 10.19M | 13.66M | 15.93M | 13.61M | 17.64M | - | 13.77M | 4.51M | 2.65M | 3.81M |
| Long Term Debt | - | - | - | - | - | - | 15.28M | 8.53M | 14.36M | 18.02M | 16.38M | 18.64M | 11.37M | 3.38M | 20.52M | 13.14M | 5.01M | - | - | - | - |
| Total Debt | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 18.62M | 5.36M | - | - | - |
| Total Equity | -40.00K | -3.71M | -13.19M | -33.34M | -52.99M | -65.89M | 17.47M | 33.85M | 73.16M | 46.66M | 33.11M | -5.34M | -36.51M | 4.25M | -41.42M | -55.75M | - | 21.81M | 14.11M | 8.00M | 17.04M |
| Shares Outstanding | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 8.24M | 16.95M | 17.03M | 49.33M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Cash Flow | -19.42M | -12.22M | -15.29M | -24.58M | -487.00K | - | -19.95M | -29.39M | -29.77M | -29.07M | -51.18M | -38.51M | - | -28.33M | -17.49M | -12.68M | -11.36M |
| Investing Cash Flow | 8.62M | 4.76M | -29.58M | 14.96M | -6.92M | - | 8.20M | 1.81M | -9.97M | -10.88M | -36.56M | 34.14M | - | 36.45M | -528.00K | 3.78M | -14.35M |
| Financing Cash Flow | 11.88M | 3.37M | 49.60M | 49.77M | 47.88M | - | 59.63M | -26.00K | 12.33M | 75.03M | 14.45M | 16.96M | - | -507.00K | 3.47M | 12.04M | 22.74M |
| Capital Expenditure | -111.00K | -4.00K | -2.02M | -826.00K | -3.29M | -5.50M | -1.46M | -3.72M | -2.40M | -819.00K | -3.47M | -1.85M | -1.83M | -364.00K | -100.00K | - | - |
| Free Cash Flow | -19.53M | -12.23M | -17.31M | -25.41M | -3.77M | - | -21.41M | -33.12M | -32.17M | -29.89M | -54.65M | -40.36M | - | -28.70M | -17.59M | -12.68M | -11.36M |
| Net Change in Cash | - | - | - | - | - | - | - | - | - | - | - | - | - | 7.61M | -14.55M | 3.14M | -2.97M |
Ratios (Annual)
Figures in %.
| Metric | Dec 2006 | Dec 2007 | Dec 2008 | Dec 2009 | Dec 2010 | Dec 2011 | Dec 2012 | Dec 2013 | Dec 2014 | Dec 2015 | Dec 2016 | Dec 2017 | Dec 2018 | Dec 2019 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Margin % | - | - | - | - | - | - | - | -22.6% | -721.7% | -103.6% | -184.1% | -483.8% | -1,660.9% | -2,368.1% | -756.3% | - | - | -2,594.3% | - | -48,157.1% |
| Net Margin % | - | - | - | - | - | -1,875.1% | -1,393.6% | -79.4% | -639.3% | -126.7% | -248.6% | -644.3% | -2,192.0% | -2,325.9% | -745.6% | - | - | -2,826.0% | - | -51,035.7% |
| ROE % | 101.4% | 73.0% | 62.0% | 38.0% | 21.8% | -115.1% | -98.6% | -32.0% | -71.5% | -73.7% | 808.6% | 141.1% | -1,108.6% | 128.5% | 72.4% | - | 218.9% | -130.4% | -162.5% | -83.9% |
| ROCE % | - | - | - | - | - | - | - | -6.5% | -51.8% | -17.4% | -35.6% | -62.5% | -34.2% | -69.7% | -84.2% | - | -60.4% | -106.3% | -97.8% | -52.0% |
Shareholding Pattern
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for TLPH
Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced that it will host a conferenc…
Talphera, Inc. Q1 2026 Earnings Call Summary
Moby summary of Talphera, Inc.'s Q1 2026 earnings call
Talphera Inc (TLPH) Q1 2026 Earnings Call Highlights: Strong NEFRO Study Progress Amid Rising ...
Talphera Inc (TLPH) reports significant advancements in its NEFRO study, while managing increased operating costs and strategic enrollment updates.
Talphera Q1 2026 Earnings Call Transcript
Talphera (NASDAQ:TLPH) reported first-quarter financial results on Wednesday. The transcript from the company's first-quarter earnings call has been provided below. This transcript is brought to you by Benzinga APIs. For real-time access to…
Talphera (TLPH) Q1 2026 Earnings Transcript
With this continued progress, we believe we are well positioned to complete enrollment in the nephro CRRT study this year. As mentioned, in early March, we announced the attainment of the 50% enrollment milestone in the nephro study.…
Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update
Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for use in medically supervised settings, today announced first quarter 2026 financial …
TLPH — Frequently Asked Questions
What is the current share price of TLPH?
As of 2026-08-05 17:25 PDT, TLPH trades at $1.35 on NASDAQ/NYSE. Its 52-week range is $0.39 to $1.46.
What is the market capitalisation of TLPH?
TLPH has a market capitalisation of $66.59M on NASDAQ/NYSE.
What is the P/E ratio of TLPH?
TLPH trades at a trailing price-to-earnings (P/E) ratio of -3.97. Its price-to-book (P/B) ratio is 3.91.
What is the return on equity (ROE) of TLPH?
TLPH has a return on equity (ROE) of -83.89%. Its return on capital employed (ROCE) is -52.04%.
Is TLPH a good stock to buy?
This page provides a data-driven analysis of TLPH, including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.